EP3693476
CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
22.2.2013EP published:
18.10.2023EP application number:
20154250.3
EPO information:
European Patent Register
Max expiry date:
21.2.2033
Title in English:
CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUSLanguage of the patent:
English
Timeline
Today
22.2.2013EP application
18.10.2023EP Publication
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056 Basel, CH
Inventor
Name:
CONG, FengAddress:
Cambridge, MA 02139, US
Name:
HAO, HuaixiangAddress:
Cambridge, MA 02139, US
Name:
HSIEH, Hsin-iAddress:
San Diego, CA 92121, US
Name:
LIU, JunAddress:
San Diego, CA 92121, US
Name:
NG, NicholasAddress:
San Diego, CA 92121, US
Name:
JIANG, XiaomoAddress:
Cambridge, MA 02139, US
Priority
Number:
201261604290 PDate:
28.2.2012Country:
US
Classification
Categories:
C12Q 1/6886